Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Sanne J. de Haart, Lisa Holthof, Willy A. Noort, Monique C. Minnema, Maarten E. Emmelot, Tineke Aarts-Riemens, Parul Doshi, Kate Sasser, Huipin Yuan, Joost de Bruijn, Anton C. M. Martens, Niels W. C. J. van de Donk, Henk M. Lokhorst, Richard W. J. Groen, Tuna Mutis

Research output: Contribution to journalArticle*Academicpeer-review

Original languageEnglish
Pages (from-to)E339-E343
JournalHaematologica
Volume101
Issue number8
DOIs
Publication statusPublished - Aug 2016

Keywords

  • abrogation
  • bone marrow stromal cell
  • cell lysis
  • deratumumab
  • multiple myeloma
  • sepantronium bromide

Cite this